• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British Journal of Cancer >ICRF-159 enhancement of radiation response in combined modality therapies. II. Differential responses of tumour and normal tissues
【24h】

ICRF-159 enhancement of radiation response in combined modality therapies. II. Differential responses of tumour and normal tissues

机译：ICRF-159在联合治疗中增强放射反应。二。肿瘤与正常组织的差异反应

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The combined effect of the chemotherapeutic agent ICRF-159 and radiation on the proliferative status of tumorormal systems has been evaluated using the Lewis lung tumour in BDF1 mice. We have previously shown that a 25 mg/kg dose of ICRF-159, given at 3h intervals X4 before irradiation, significantly enhanced tumour growth retardation relative to a single dose of 100 mg/kg before irradiation. Whilst both single and fractionated drug treatments produced a transient inhibition of cell proliferation, comparisons of the temporal recovery from the antiproliferative effect of radiation in both tumour and intestinal epithelium suggested that single acute doses of ICRF-159 fail to potentiate the radiation response of either tissue. Protracted drug administration before irradiation, however, markedly decreases the post-radiation proliferative recovery of the tumour, without significantly altering intestinal recovery. The data suggest that both drug concentration and/or exposure time determine the interactions seen with combined modes.
机译：使用Lewis肺肿瘤在BDF1小鼠中评估了化学治疗剂ICRF-159和放射线对肿瘤/正常系统增殖状态的联合作用。先前我们已经表明，相对于辐射前单剂量100 mg / kg，在辐射前3小时间隔X4给予25 mg / kg剂量的ICRF-159，显着增强了肿瘤生长迟缓。尽管单一药物治疗和分次药物治疗均会短暂抑制细胞增殖，但对肿瘤和肠上皮中放射线抗增殖作用的暂时恢复的比较表明，单次急性剂量的ICRF-159不能增强任一组织的放射线反应。然而，在放射线前长时间给药会显着降低放射线后肿瘤的增生性恢复，而不会显着改变肠道的恢复。数据表明，药物浓度和/或暴露时间都决定了组合模式下的相互作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号